Unique properties of metal complexes, such as structural diversity, adjustable ligand exchange kinetics, fine-tuned redox activities, and distinct spectroscopic signatures, make them exciting scaffolds not only for binding to nucleic acids but increasingly also to proteins as non-traditional targets. This feature article discusses recent trends in this field. These include the use of chemically inert metal complexes as structural scaffolds for the design of enzyme inhibitors, new strategies for inducing selective coordination chemistry at the protein binding site, recent advances in the development of catalytic enzyme inhibitors, and the design of metal complexes that can inject electrons or holes into redox enzymes. A common theme in many of the discussed examples is that binding selectivity is at least in part achieved through weak interactions between the ligand sphere and the protein binding site. These examples hint to an exciting future in which ''organiclike'' molecular recognition principles are combined with properties that are unique to metals and thus promise to yield compounds with novel and unprecedented properties.
Introduction
The design of synthetic molecules that are capable of selectively perturbing the function of individual biomolecules is at the heart of chemical biology and medicinal chemistry. Strikingly, the stark majority of such compounds is of purely organic origin. 1 This may seem surprising since chemists have the opportunity to recruit elements with fine-tuned characteristics from all over the periodic table of elements. For example, unique properties of metal complexes may offer untapped opportunities for the development of novel probes to unravel the function of proteins, the design of sensors, as well as the generation of drugs and diagnostics. The most notable features of metal complexes are listed below:
A variety of coordination numbers and geometries of metal complexes result in a high structural diversity. This might be exploited for the design of pharmacophores that are not accessible with purely organic elements.
Metal complexes are readily susceptible to combinatorial synthesis since compounds are built from a common center and ligand exchange reactions often proceed in a predictable fashion. This allows one to discover complexes with desired properties by combinatorial library synthesis followed by high-throughput screening.
Unique and tunable properties of metals, such as adjustable ligand exchange kinetics, catalytic properties, redox activities, Lewis acidities, access to radical species, magnetic properties, spectroscopic properties, and radioactivity, can be exploited for the generation of tailored function.
This feature article will focus on recent advances in the design of metal-containing compounds as protein binders. Emphasis will be placed on the strategies for achieving target binding along with the particular functions of the involved metals.
Metal complexes as inert scaffolds
From tetrahedral carbon to octahedral metal Metal complexes can complement purely organic molecules by serving as structural scaffolds for the design of compounds with bioactivity. Whereas carbon is limited in binding geometries to linear (sp-hybridization), trigonal planar (sp 2 -hybridization), and tetrahedral (sp 3 -hybridization) geometries, transition metals offer the opportunity to go beyond the coordination number four. For example, it is intriguing that an octahedral center with six different substituents is capable of forming 30 stereoisomers compared to just two for an asymmetric tetrahedral carbon. This number of stereoisomers can be correlated with the ability of this center to build structures (Fig. 1 ). This means, that by raising the number of substituents from four (tetrahedral center) to six (octahedral center), the ability of this center to organize substituents in the three dimensional space increases substantially. In addition, using a hexavalent center may provide new synthetic opportunities for accessing globular shapes by building structures from a single center in six different directions. Interestingly, until our work on ruthenium complexes as kinase inhibitors, only very few examples have been reported in which structural properties of metal complexes are exploited as pharmacophores with novel geometries. 2 
Metal complexes as kinase inhibitors
Starting at the University of Pennsylvania in 2002, my group decided to systematically explore the ability of metal centers to help creating unique and defined molecular structures for the design of enzyme inhibitors. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] We envisioned that a substitutionally inert metal center could complement organic elements, serving as a stable imaginary ''hypervalent carbon'' with an improved ability to build structures.
We chose protein kinases as the principal target because mutations and deregulation of protein kinases play causal roles in many human diseases, making kinases an important therapeutic target. In addition, kinases form one of the largest family of enzymes with very conserved ATP binding sites for which the design of selective organic inhibitors has proven to be highly challenging.
The class of ATP-competitive indolocarbazole alkaloids (e.g. staurosporine, Fig. 2(a) ) was used as an inspiration and initial lead structure. According to our design, the indolocarbazole alkaloid scaffold is replaced by metal complexes in which the main features of the indolocarbazole aglycon are retained in the metal-chelating pyridocarbazole ligand, whereas the carbohydrate is substituted by a globular metal fragment (Fig. 2(a) ). Following this strategy, nanomolar and even picomolar ATP-competitive ruthenium-based inhibitors for different protein kinases were discovered, some of them by combinatorial chemistry, some by rational design, or a combination thereof. 3 Such compounds are air-stable, stable in water, and in buffer solutions containing millimolar concentrations of thiols. This stability is due to the inert character of typical coordinative bonds to ruthenium. This, together with its modest price of the starting material RuCl 3 , its low toxicity, and its predictable and established synthetic chemistry, makes ruthenium maybe the most attractive metal for establishing octahedral or pseudo-octahedral (e.g. half-sandwich) coordination geometries. We further demonstrated that such ruthenium compounds can exert their selective function within mammalian cells, Xenopus embryos, and zebrafish embryos. Recent cocrystal structures confirm that these compounds bind to the ATP-binding site of protein kinases. For example, Fig. 2(b) displays the octahedral organoruthenium complex L-FL172 (see also Fig. 2(c) ) bound to the ATP-binding site of the protein kinase PAK-1. 18 PAK-1 has a particularly open ATP-binding site, making it difficult to target with conventional organic scaffolds, but especially suitable for filling it with bulky and rigid octahedral complexes. In L-FL172, the distance between the oxygen atom of the CO ligand and the para-carbon of the pyridine in trans serves as a rigid yardstick of about 8 Å which is well accommodated by the active site of PAK1, but not most other protein kinases. It is noteworthy that the D-enantiomer is a significantly weaker binder for PAK1 (27-fold) . Such a stereodifferentiation is expected for the molecular recognition of a chiral active site.
In summary, over the last five years, our group reported highly potent organometallic inhibitors for the kinases GSK-3, Pim-1, MSK-1, PAK-1 and PI3K (Fig. 2(c) ), thus demonstrating the generality of the design strategy. We deposited seven cocrystal structures of metal complexes with kinases in the PDB (Pim-1 with Ru:2BZH, 2BZI, 2OI4, 2 BZJ; Pim-2 with Ru:2IWI; PI3Kg with Ru:2CST; Pim-1 with Os:3BWF). In all these crystal structures, the metal exerts a purely structural role. Some of the published inhibitors belong to the most potent and selective compounds known for their respective kinases. We hypothesize that the high selectivities are caused by the rigidities of these scaffolds. The complex EA1 (Fig. 2(c) ) and derivatives thereof have also been demonstrated to display promising anticancer activities in several cancer cell lines and in a melanoma spheroid model, 12 and it will now be important to investigate potential efficacy in an animal model.
Ruthenium polypyridyl complexes as acetylcholinesterase inhibitors
In pioneering work, Dwyer investigated the biological activities of a variety of metal complexes and discovered, among others, the bacteriostatic, bacteriocidal, and antitumor activities of chemically inert cationic polypyridyl complexes of ruthenium(II). [19] [20] [21] [22] [23] Dwyer concluded that due to the marked chemical and biological stability of such ruthenium cations, their biological effects must be due to the cation as a whole and not to its individual constituents. Such ruthenium complexes also caused paralysis and respiratory failure after intraperitoneal injection into mice at high concentrations, apparently due to their potent direct inhibition of acetylcholinesterase (AChE). These cationic ruthenium complexes most likely bind through a combination of electrostatic and hydrophobic interactions at the peripheral anionic site of AChE which is located at the rim of the active-center gorge. 24 Our group recently followed up on these discoveries and screened a small library of trisheteroleptic ruthenium polypyridyl complexes, synthesized on solid phase, against AChE and identified complex SPM1 to be a nanomolar inhibitor (IC 50 = 200 nM) for AChE from E. electricus (Fig. 3(a) ). 25 Compared to the parent [Ru(phen) 3 ]Cl 2 (IC 50 = 10 mM) this is an improvement by a factor of around 50-fold, just by functionalizing the periphery of this ruthenium polypyridine scaffold. It is likely that further improvements in the affinity of this scaffold would be possible in a straightforward fashion through the synthesis and screening of larger libraries.
Iron Schiff-base complexes as inhibitors of trypsin and thrombin
Tanizawa's group developed Cu(II) and Fe(III) Schiff base chelates as inhibitors for the serine proteases thrombin and trypsin. 26, 27 The Schiff bases were obtained from 4-formyl-3-hydroxybenzamidines or 3-formyl-4-hydroxybenzamidines and amino acids. Most interestingly, a cocrystal structure of bis(p-amidinosalicylidene-L-alanilato)iron(III) (Fig. 3(b) , 1, K i = 1.6 mM) with bovine b-trypsin revealed that the octahedrally coordinated iron is not involved in any direct interactions with the active site and has a purely structural role. 26 One of the phenylamidinium residues forms a bidentate salt bridge with the side chain of Asp189 at the bottom of the hydrophobic selectivity (S1) pocket, in analogy to many related organic inhibitors that are based on the phenylamidinium scaffold. Notably, the catalytic triad is not involved in any interactions with the iron chelate. Due to the facile access of these Schiff base chelate complexes, a variation of the aldehyde moiety, amino acid residues, and metal ions, should allow for quick structure-activity-relationships for improving the binding affinities. In fact the authors recently reported copper and iron complexes as nanomolar inhibitors for thrombin. 27 However, in the case of the octahedral chelates, the use of labile metal ions prevents the synthesis of mixed ligand complexes. Thus, the utilization of kinetically more inert complexes of ruthenium, rhodium or iridium instead of iron should enable a more sophisticated design of the ligand sphere with the prospect of achieving higher affinities and selectivities.
Ruthenium-oxo-oxalato cluster as inhibitor of HIV-1 reverse transcriptase
Many polyoxometallates (POMs) show promising antiviral activities in vitro and in vivo. 28 POMs active against HIV-1 exhibit at least three modes of actions: Interference with the HIV gp120/CD4 interaction, inhibition of HIV reverse transcriptase (RT), and/or inhibition of HIV protease. Favorable electrostatic interactions between the polyanionic POMs and cationic binding sites at the protein component appear to be very important. Unfortunately, most POMs are not stable under physiological conditions, making it difficult to determine the active species. This is however not the case for the ruthenium-oxo-oxalato cluster Na 7 [Ru 4 (m 3 -O) 4 (C 2 O 4 ) 6 ] (Fig. 3(c) ), which is a particularly potent inhibitor of HIV RT with an IC 50 value of 1.9 nM. 29 This cluster has been demonstrated to be stable under physiological conditions and shows promising anti-HIV-1 activity without being cytotoxic.
Metal coordinated pentaazacrowns as b-turn mimics
Metal coordination can control the conformation of a macrocycle. For example, Marshall and coworkers propose the utilization of metal complexes of chiral azacrowns (MACs), derived from the reduction of cyclic peptides, as a strategy for controlling the conformation and fixing chiral side chains in orientations comparable with those of peptide b-turns. 30, 31 In this design, the metal is buried in the middle only acting as a glue to keep all the pharmacophore groups oriented together in the right directions. Crystal structures of MACs and calculated solution structures demonstrate that MACs provide preferred templates closely resembling the overall direction of reverse-turn motifs as well as the spatial locations of side chains. For example, it was suggested that the MAC complex 2 (Fig. 3d) should serve as a nonpeptidic inhibitor of amylase by mimicking the active reversed b-turn sequence Trp18-Arg19-Tyr20 of the proteinaceous amylase inhibitor tendamistat. 32, 33 However, it is noteworthy that Riley and coworkers are developing related MACs for clinical use based on their high catalytic dismutase activity, thus demonstrating that the metal center in such MACs can exert functions beyond their structural roles. 34 
Metal coordination to amino acid side chains
Whereas in the previous section metal complexes were designed with the metal center exerting a purely structural role, here examples will be discussed in which the metal forms one or even multiple coordinative bonds to residues at the protein surface or within the active site.
Spurred by the discovery of the guanine crosslinking properties of the anticancer drug cisplatin, metal complexes have traditionally been targeted to the nucleophilic guanine bases of DNA and proteins or enzymes were more or less neglected. However, the available data of the sequenced human genome together with efforts to understand the structure and function of every single human protein results in fastly growing amounts of data available for targeted therapy. In this respect, in particular the amino acids cysteine, histidine, and tyrosine, constitute exquisite protein binding sites for metal complexes with vacant coordination sites. In order to create coordinating metal complexes with controlled biological properties, the ligand exchange kinetics can be adjusted by the metal, its oxidation state, the (semi)labile ligand, and the remaining coordination sphere. However, in order to achieve a high degree of target selectivity it is necessary to combine a fine-tuned reactivity of the metal center with molecular recognition of the target site by the ligand sphere of the metal complex. The here presented examples indicate the interplay between coordination chemistry and molecular recognition through weak interactions mediated by the ligand sphere.
Oxorhenium(V) complex as selective cathepsin B inhibitor
Fricker et al. discovered a simple oxorhenium(V) complex 3 (Fig. 4(a) ) with an impressive low nanomolar binding affinity for cathepsin B (IC 50 = 9 nM). 35, 36 Cathepsin B is a cysteine protease in which a cysteine is activated within a catalytic triad, resulting in an increased reactivity of the cysteine nucleophile. Mechanistic studies reveal that the rhenium complex is an active site directed time-dependent slowly reversible inhibitor in the presence of an excess of exogenous cysteine, thus indicating a coordination to the active site cysteine by substituting the labile chloride ligand. This mode of action is analogous to the majority of organic cysteine protease inhibitors which form a reversible or irreversible covalent bond with the reactive cysteine in the active site. However, it is intriguing that this compound showed a 44-fold selectivity for cathepsin B over the related cathepsin K. A structure-activity relationship around the tridentate 2,2 0 -thiodiethanethiolate ligand demonstrated the importance of a particular coordination sphere which is most likely dictated by the size and shape of the active site of cathepsin B.
Co(III) Schiff-base conjugated to thrombin active site-directed peptides
Meade and Gray et al. demonstrated the inhibition of the human serine protease a-thrombin with a Co(III) Schiff base complex conjugated to an active site-directed peptide (4a, Fig. 4(a) ). 37 Selectivity is conferred by the reversible binding of the peptide component, while an irreversible inhibition is believed to occur through cobalt(III) coordination to histidines in the active site or near the active site.
Cu(II) complexes as HIV-protease inhibitors
In another example of metal complexes as protease inhibitors, copper(II) complexes were designed as HIV-1 protease inhibitors. [38] [39] [40] Complex 5 (Fig. 4(a) ) displays a K i value of 1 mM for HIV-1 protease. Molecular modeling suggests that the pyridyl group occupies the S2/S2 0 pockets whereas the trimethoxybenzyl group occupies the larger S1/S1 0 subsite. 40 The copper ion is positioned to coordinate the structural catalytic water molecule in the active site and a second water ligand interacts with the flap residue of Ile50. However, such Cu(II) complexes are kinetically very labile and CuCl 2 itself displays the same IC 50 value of 1 mM and is known to inhibit HIV-1 protease by targeting the thiol group of cysteines.
Targeting zinc fingers with platinum complexes
The Farrell group designed platinum complexes to selectively target zinc finger proteins. 41, 42 The reaction of the platinum complex trans-[PtCl(9-EtG)(py) 2 ] + (6, Fig. 4(a) ) with the C-terminal zinc finger of the HIV NCp7 protein results in a coordination of the platinum complex to the zinc finger under zinc ejection and loss of tertiary structure. The proposed mechanism involves an initial noncovalent recognition in which the platinated purine nucleobase mimics the natural nucleic acid-tryptophan recognition interaction of zinc finger peptides by stacking the coordinated 9-ethylguanine ligand against a tryptophan of NCp7. In a related fashion, Louie and Meade used oligonucleotide-tethered cobalt salen complexes 4b (Fig. 4) to selectively target zinc fingers. 43 
Vanadium complexes as phosphatase inhibitors
The isostructural nature of the simple vanadate (VO 4
3À
) and phosphate together with the ability of vanadium(V) to easily change its coordination number and geometry results in its strong effect on the function of a large variety of phosphoryl transfer enzymes. 44 For example, in the course of the catalytic cycle of phosphatases leading to the hydrolysis of a phosphate, the phosphorus passes through a pentacoordinated transition state that can be trapped by a stable pentacoordinated vanadate which serves as a transition state analog. 45 Fig. 4(b) shows the example of a tyrosine phosphatase complexed with the inhibitor vanadate through an active site cysteine. 46 In a modified mode of action, pervanadates can serve as strong oxidants, for example causing an irreversible inhibition by oxidizing the catalytic cysteine of protein tyrosine phosphatases. 47 This effectiveness of vanadate to inhibit tyrosine phosphatases appears to be responsible for the insulin-mimetic effect of many vanadate complexes.
A strategy to render vanadium compounds more selective towards a particular target is the introduction of ligands into the coordination sphere. 48 For example, a recent publication by Rosivatz and Woscholski et al. described the design of a selective vanadyl inhibitor for the phosphinositide 3-phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10). 49 PTEN is characterized by a wide and deep catalytic pocket which distinguishes it from other cysteine-based phosphatases. 50 The bulky vanadyl complex 7 (Fig. 4(a) ), 51 containing two 3-hydroxypicolinate ligands, one water molecule, and an oxo ligand, appears to fit well into this pocket (IC 50 = 35 nM), but not into those of other cysteinebased phosphatases such as PTPb, SAC, MTM and SopB.
Binding of gold complexes to proteins
Anthiarthritic gold(I)-phosphine compounds are prodrugs which undergo facile ligand displacement reactions. 52 Due to the softness of Au(I), the critical target sites are thought to be cysteine residues in proteins and enzymes. However, Sadler et al. investigated the reactions between the enzyme cyclophilin and the antiarthritic complex [Au(PEt 3 )Cl] and reported a crystal structure of Au(I) phosphane adduct, in which, unexpectedly, Au(I) binds to a histidine residue despite the presence of four cysteine thiol groups. 53 Becker et al. reported the effects of highly potent phospholecontaining gold and platinum complexes on human disulfide reductases. 54 An X-ray crystal structure of human glutathione reductase, after reaction with the gold phosphole complex 8, revealed an almost linear S-Au(I)-S coordination in the active site (Fig. 4(c) ), confirming that the phosphine-gold chloride complexes act as prodrugs with a stepwise ligand replacement. Furthermore, one surface-exposed cysteine (Cys284) is complexed to 8 by replacement of the chloride, showing how the phosphole ligand forms hydrophobic contacts with neighboring surface residues (Fig. 4(c) ).
Recognition of the surface histidine pattern
Mallik et al. designed cupric iminodiacetate chelate complexes which recognize the unique pattern of histidine residues on protein surfaces. [55] [56] [57] [58] For example, carbonic anhydrase contains five histidines exposed on its surface and molecular modeling led to the design of the tris-chelate 9 (Fig. 4(d) ), which binds carbonic anhydrase with a binding constant of 3 Â 10 6 M À1 and is selective over chicken-egg albumin (six histidines on the surface, K o 1 Â 10 3 M À1 ). 55, 56 In a variation of this concept, ''two-prong'' inhibitors were designed for carbonic anhydrase in which an organic benzenesulfonamide active site inhibitor was tethered to cupric iminodiacetate through designed linkers. For example, the high-resolution crystal structure in Fig. 4(d) demonstrates that the organic sulfonamide inhibitor BR30 binds within the conical active site cleft and coordinates with the deprotonated sulfonamide nitrogen to the catalytic zinc ion at the bottom of the cleft. 57 This brings the copper chelate in position to coordinate to His64 which is located halfway out of the active site cleft and serves as a proton shuttle during catalysis. This rendered the otherwise weak benzenesulfonamide inhibitor into a nanomolar and more selective inhibitor for human carbonic anhydrase II (IC 50 = 28 nM). This concept has recently been expanded to a ''multi-prong'' design in which an active site directed ligand is connected to multiple histidinerecognizing cupric iminodiacetate chelates. 58 Metal-dependent binding of AMD3100 to CXCR4 p-Xylylbicyclam (AMD3100) is in phase II clinical trials for stem cell transplantation and also a highly potent anti-HIV agent by binding to the CXCR4 co-receptor which assists in the entry of HIV into cells and anchors stem cells in the bone marrow. 59 Cyclam has a high affinity for Zn(II) and should therefore form a Zn(II) complex in the blood plasma. 60 Interestingly, the affinity of AMD3100 for the CXCR4 receptor is enhanced after Zn(II) coordination by a factor of 36. 61 The Zn(II) influences the conformation of the cyclam which probably affects the binding affinity. 62 Modeling studies suggest that in addition to a variety of hydrophobic and H-bonding interactions, one of the Zn(II) centers coordinates axially to an aspartate carboxylate oxygen. 63 The Sadler group investigated the binding of copper and nickel cyclams to lysozyme as a model to study the recognition of proteins by metallomacrocycles. 64, 65 For example, the X-ray crystal structure of hen-egg white lysozyme soaked with Ni II 2 -xylylbicyclam 10 (Fig. 4(e) , M = Ni II ) reveals two major binding sites, with one being characterized by a coordination of the Ni(II)-ion to an aspartate carboxylate group (Asp101) in addition to hydrophobic interactions of the cyclam ring with two tryptophan residues (Trp62 and Trp63). 65 This example demonstrates the capability of metallomacrocycles to combine molecular recognition mediated by the macrocycle with the ability to coordinate to the central metal ion through vacant axial coordination sites.
Catalytic metal complexes
Metal complexes serve as highly efficient everyday catalysts for organic transformations. It is therefore an appealing strategy to make use of metal catalysts for deactivating or functionalizing desired proteins. This concept may lead to the design of reagents for the modification of proteins with imaging tags, and even to the design of catalytic drugs that are able to recognize and degrade multiple copies of a biomolecular target. 66 
Artificial proteases
Su and coworkers have designed artificial proteases by tethering the peptide cleaving Cu II and Co III complexes of 1,4,7,10-tetraazacyclododecane (cyclen) to peptide nucleic acids, peptides, and small molecule binder. 67 For example, the conjugate 11 (Fig. 5 ) was found to catalytically cleave the enzyme peptide deformylase between Gln152 and Arg153 within the C-terminal a-helix. 68 In a similar fashion, artificial proteases against myoglobin, 69 amyloid b peptides, 70 and angiotensin II 71 were designed.
Enzyme inactivation by catalytic oxidation of active site residues
Cowan reported the design of metallopeptide conjugates as catalytic inactivators of enzymes by using the amino terminal copper/nickel (ATCUN) binding motif. [72] [73] [74] For example, in the sulfonamide-metallopeptide conjugate 12 (Fig. 5) , the sulfanilamide pharmacophore targets the Cu 2+ -bound GlyGly-His (GGH) peptide motif to the active site of carbonic anhydrase. 74 GGH has a high affinity for the redox active Cu 2+ with the most likely active species being a Cu 2+ -associated hydroxyl radical or Cu 3+ QO species. Under oxidative conditions (no reducing agent present) and subsaturating conditions a time-dependent inactivation is observed. A residual 20% activity of carbonic anhydrase was observed and explained with the intrinsic reactivity of the Cu complex towards its own substrate. No protein cleavage was observed but several histidine residues and two tryptophans in proximity to the active site were oxidatively modified. Apparently, the oxidation of amino acid residues was restricted to the proximity of the active site where the inhibitor tail with the Cu-GGH motif would be oriented.
Ru(II) tris-bipyridyl as light-activated singlet oxygen generator
In the technique CALI (chromophore-assisted light inactivation), 75 a chromophore capable of generating reactive singlet oxygen when irradiated is delivered to a target protein. Due to the short lifetime of the singlet oxygen, only proteins in proximity to the singlet oxygen generator will become deactivated by oxidation, thus providing spatial and temporal control over protein inactivation. [Ru(bpy) 3 ] 2+ is an efficient photocatalyst for singlet oxygen generation and can be used as a warhead to deactivate the function of target proteins or enzymes. 76, 77 In a proof-of-principle experiment, Kodadek demonstrated this by deactivating the function of luciferase in a designed reporter system. 76 For this, a mutant haloalkane dehalogenase, the so called HaloTag protein (HTP), was genetically fused to luciferase which served as the reporter. The conjugate made out of [Ru(bpy) 3 ] 2+ and a halogenoalkane (13, Fig. 5 ) reacts irreversibly with the HaloTagluciferase fusion protein by forming a carboxylic ester through an active site carboxylate of HaloTag (see Fig. 5 , bottom right). This brings the chromophore [Ru(bpy) 3 ] 2+ in close proximity to luciferase and the subsequent UV-irradiation produces reactive singlet oxygen, resulting in its deactivation which can be conveniently monitored by luminescence measurements. The success of this strategy was verified in cell extract and even within living cells.
Miscellaneous Molecular wires to probe active site of redox enzymes
The Gray laboratory developed a powerful photochemical method for injecting electrons and holes into buried active sites of redox proteins by using so-called ''molecular wires''. [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] Such molecular wires consist of a tail group that makes contact to the active site and a redox active metal complex as a head group that is tethered to the tail group through a linker which spans the distance between the bottom of the active site and the protein surface. This design allows one to investigate mechanistic questions associated with redox enzymes and may be developed into a highly sensitive and selective detection method. Over the last 10 years, the strategy has been applied to probe a variety of proteins, such as cytochrome P450, [78] [79] [80] [81] [82] myoglobin, 83 inducible nitric oxide synthase, 84, 85 and copper amine oxidase. 86, 87 Multiple crystal structures of molecular wires that access the metal sites of redox enzymes have been reported over the last few years. [79] [80] 86, 87 For example, Fig. 6(b) shows the binding of the ruthenium(II) molecular wire 14 ( Fig. 6(a) ) to the amine oxidase of Arthrobacter globiformis (AGAO). 87 Complex 14 is a potent inhibitor of AGAO with nanomolar affinity (K i = 32 nM) and this affinity is independent of the chirality of the [Ru(phen)(bpy) 2 ] 2+ head group. The wire binds in the AGAO active-site channel with the dimethylaniline tail group being in contact with the trihydroxyphenylalanine quinone cofactor of the enzyme (Fig. 6(b) ). The interactions of this tail with the active site cavity are mainly through hydrophobic interactions. The C 4 -linker stretches through the channel, enabling the ruthenium head group to fit into the end of the active site channel and contributing to the high affinity by hydrophobic contacts with protein surface residues. It can be envisioned that this scaffold might be rendered even more potent by modifying the ruthenium head group through functionalizing the polypyridyl ligands in a structure-based and/or combinatorial fashion in order to improve the contacts to the entrance of the active site channel.
Ferrocifen, an organometallic prodrug
Ferrocifen 15 (Fig. 6(a) ) is a derivative of the anticancer drug tamoxifen in which a phenyl group is replaced by a ferrocene moiety. [88] [89] [90] [91] Tamoxifen is the front-line chemotherapeutic agent for patients with hormone-dependent breast cancer. The antiproliferative action of tamoxifen results from the competitive binding to the estrogen receptor ERa, thus repressing the estradiol-mediated DNA transcription in the tumor tissue. The activity of ferrocifen was believed to follow the same principle. 89 However, recently it was shown that ferrocifen also acts against tumor cells that lack this estrogen receptor, thus indicating a yet unknown mode of action. Interestingly, the isostructural ruthenocene derivative of 15 also acts as an antiestrogen in hormone-dependent breast cancer cells but lacks the antiproliferative effect of ferrocifen against hormone-independent cells. 90 This indicates that the function of ferrocifen in hormoneindependent cells is at least in part due to the redox activity of the ferrocene unit. A recent electrochemical study by Jaouen, Amatore and co-workers revealed that it may be a quinone methide oxidative product that is involved in the mode of action. 91 
Cobalt-alkyne complexes of aspirin as COX inhibitors
The cobalt-alkyne derivative 16 (Fig. 6(a) ) of the drug aspirin (acetylsalicylic acid) exhibits high cytotoxicity in breast cancer cell lines. 92 This cytotoxicity correlates with cyclooxygenase (COX) inhibition and it can be speculated that 16 binds to cyclooxygenase in a fashion similar to aspirin followed by an acetylation of a surface residues or even a reaction of the cobalt-alkyne complex.
Conclusions
This collection of recent literature illustrates the latest emerging strategies for targeting metal complexes to proteins, particularly the use of the unique shapes of metal complexes as structural scaffolds, the linkage of metal complexes to known organic protein binders, the application of coordination modes that are unique to the target site, or a combination thereof. Many current approaches use modes of molecular recognition that are analogous to typical organic protein binders and enzyme inhibitors. Target selectivity together with aspects of metal complex stabilities in biological systems will be the two most critical aspect for the next generation of metal-containing compounds used in chemical biology and medicinal chemistry. In such compounds, defined molecular recognition will be combined with properties that are unique to metal complexes, such as photophysical signatures or catalysis, in order to create compounds with novel and unprecedented properties.
